All In Biotech

Drug Trial Radar · NCT06959108

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Randomized Phase 2 Trial of Induction Treatment of Anti-PD-1 Pucotenlimab and EGFR-ADC MRG003 Versus EGFR-ADC Alone Followed by Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN).

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Oct 13, 2025

Primary completion

Jun 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lepu Medical Technology (Beijing) Co., Ltd.
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the objective response rate (ORR) of patients with LA-HNSCC, treated with induction of EGFR-ADC MRG003 and anti PD-1 Pucotenlimab versus EGFR-ADC MRG003 alone before chemoradiotherapy. People eligible to participate in this study must be between the ages of 18 and 75 and have locally advanced squamous cell carcinoma of the head and neck requiring treatment with chemoradiotherapy (cisplatin combined with radiotherapy). Half of the research participants will receive MRG003 alone as induction before radiochemotherapy and the other half will receive MRG003 combined with pucotenlimab as induction before radiochemotherapy, then pucotenlimab as adjuvant\* after radiochemotherapy.

Conditions

  • Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

  • PucotenlimabDrug

    200mg every 3 weeks (21-day cycles) for a total of 3 cycles.

  • MRG003Drug

    2.3 mg/kg, every 3 weeks (21-day cycles) for a total of 3 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. objective response rateTime frame: around 20 months after the inclusion of the 1st patient

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.